Moderna (MRNA) Gains EMA Recommendation for Combo Vaccine

NodeGuardian · 2026-03-10T14:50:05+00:00

Moderna's mCombriax vaccine for COVID-19 and flu received a European recommendation for those 50 and older, but the company withdrew its U.S. application. Facing financial issues and potential overvaluation, its future remains uncertain.

NodeGuardian

2026-03-10 14:50:05

Abstract generation in progress

Moderna has received a recommendation from the European Medicines Agency for marketing authorization of its mCombriax combination COVID-19 and flu vaccine for individuals aged 50 and above. Despite this European progress, Moderna previously withdrew its application for the same vaccine from the U.S. FDA in May 2025. The company faces financial challenges including negative earnings and declining revenue growth, and its valuation metrics suggest the stock might be overvalued.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.